At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,238 enrolled
Drug / intervention
Dapsone Gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Dapsone Gel and Dapsone Gel Vehicle for Acne Vulgaris. Completed, enrolled 2,238 participants across 3 sites in 2 countries.
Detailed Summary
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
CollaboratorsAllergan
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartNov 2013
Primary CompletionOct 2014
TodayJul 2026
First PostedNov 1, 2013
Enrollment StartNov 1, 2013
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.7 years ago
Interventions
Dapsone Geldrug
Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Dapsone Gel Vehicledrug
Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.